Suppr超能文献

慢性肾脏病患者的高血压控制与抗高血压治疗

Hypertension control and antihypertensive therapy in patients with chronic kidney disease.

作者信息

Unni Sudhir, White Kellee, Goodman Michael, Ye Xiangyang, Mavros Panagiotis, Bash Lori D, Brixner Diana

机构信息

Pharmacotherapy Outcomes Research Center, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA;

Arnold School of Public Health, Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, South Carolina, USA;

出版信息

Am J Hypertens. 2015 Jun;28(6):814-22. doi: 10.1093/ajh/hpu215. Epub 2014 Nov 24.

Abstract

BACKGROUND

Hypertension is a major risk factor in the progression of chronic kidney disease (CKD). Although hypertension is more prevalent and treated more often among CKD patients, it is less likely to be controlled. Current guidelines recommend the use of multiple antihypertensive agents to achieve optimal blood pressure (BP) control. However, BP control attained by number and type of antihypertensive therapy according to CKD stage has not been examined thoroughly.

STUDY DESIGN

Cross-sectional analysis of an electronic medical record (EMR) database.

SETTING AND PARTICIPANTS

A total of 115,608 patients with CKD (Stages 1-4) and diagnosed or treated hypertension in General Electric Centricity EMR from 1996 to 2012.

OUTCOME

BP control, based on JNC 7 guidelines, was defined as less than 130/80 mm Hg.

MEASUREMENTS

BP and antihypertensive therapy use was obtained from the EMR. The Cockcroft-Gault equation was used to calculate estimated glomerular filtration rate and classify CKD stage.

RESULTS

Overall prevalence of BP control was 24.3%. BP control varied by CKD stage and number of antihypertensive therapy. In multivariable analysis, younger age was less likely to be associated with BP control, regardless of CKD stage. Multiple antihypertensive therapy use and BP control was strongest among CKD Stage 2 (odds ratio (OR): 1.41; 95% confidence interval (CI): 1.05, 1.90). Diuretic use was less likely to be associated with BP control among CKD Stage 1 (OR: 0.71; 95% CI: 0.59, 0.87) and 2 (OR: 0.78; 95% CI: 0.72, 0.85).

LIMITATIONS

Information on antihypertensive prescription fill data and adherence to medication regimens was unavailable.

CONCLUSIONS

This study highlighted the need to pay closer attention to achieving BP treatment goals for younger individuals with CKD. More research is needed to assess the extent to which specific combinations of antihypertensive drugs leads to adequate BP control.

摘要

背景

高血压是慢性肾脏病(CKD)进展的主要危险因素。虽然高血压在CKD患者中更为普遍且治疗更为频繁,但血压得到控制的可能性较小。当前指南推荐使用多种抗高血压药物以实现最佳血压(BP)控制。然而,根据CKD分期,抗高血压治疗的数量和类型所实现的血压控制情况尚未得到充分研究。

研究设计

对电子病历(EMR)数据库进行横断面分析。

设置与参与者

1996年至2012年期间,共有115,608例CKD(1 - 4期)患者在通用电气Centricity EMR中被诊断或治疗高血压。

结果

根据美国国家联合委员会第7版(JNC 7)指南,血压控制定义为低于130/80 mmHg。

测量

从EMR中获取血压和抗高血压治疗的使用情况。使用Cockcroft - Gault方程计算估计肾小球滤过率并对CKD分期进行分类。

结果

血压控制的总体患病率为24.3%。血压控制因CKD分期和抗高血压治疗的数量而异。在多变量分析中,无论CKD分期如何,年龄较小者血压得到控制的可能性较小。在CKD 2期,使用多种抗高血压治疗与血压控制的关联最强(优势比(OR):1.41;95%置信区间(CI):1.05,1.90)。在CKD 1期(OR:0.71;95% CI:0.59,0.87)和2期(OR:0.78;95% CI:0.72,0.85),使用利尿剂与血压控制的关联较小。

局限性

无法获得抗高血压处方配药数据和药物治疗依从性的信息。

结论

本研究强调需要更加关注为年轻的CKD患者实现血压治疗目标。需要更多研究来评估特定抗高血压药物组合在何种程度上能实现充分的血压控制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验